Technology
Fusion Biopsy Market is expected to generate a revenue of USD 1448.15 Million by 2032, Globally, at 8.9% CAGR: Verified Market Research®
Published
2 years agoon
By
Verified Market Research®, a leading provider of business intelligence and market analysis is thrilled to announce the release of its comprehensive and authoritative report on the Fusion Biopsy Market. This in-depth study provides industry leaders, medical device manufacturers, healthcare providers, and investors with critical insights into the evolving landscape of fusion biopsy technologies.
LEWES, Del., March 5, 2025 /PRNewswire/ — The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was valued at USD 732.13 Million in 2024 and is expected to reach USD 1448.15 Million by the end of the forecast period.
The Fusion Biopsy Market is witnessing rapid growth, driven by increasing adoption of precision diagnostic techniques for prostate cancer and other malignancies. Fusion biopsy, which combines MRI and ultrasound imaging, has emerged as a game-changer in early cancer detection and treatment planning. The report delves into market dynamics, including technological advancements, regulatory updates, and competitive strategies shaping the industry.
Key Highlights of the Market Report:
Market Size & Growth Projections – Detailed analysis of the current market valuation, CAGR, and forecasted growth potential through 2032.Technological Innovations – Insights into the latest advancements in MRI-ultrasound fusion biopsy techniques, AI-powered imaging, and real-time navigation systems.Competitive Landscape – Profiles of key players, including mergers, acquisitions, and strategic partnerships that are redefining the market.Regional Analysis – Market trends and investment opportunities across North America, Europe, Asia-Pacific, and other emerging regions.End-User Insights – Adoption trends across hospitals, diagnostic centers, and research institutions.
Why This Report Matters?
With the increasing burden of cancer cases worldwide, precision diagnostics are more crucial than ever. Industry stakeholders seeking data-driven insights on investment opportunities, emerging technologies, and strategic positioning will find this report invaluable.
For more information or to purchase the report, please contact us at: https://www.verifiedmarketresearch.com/download-sample?rid=480739
Browse in-depth TOC on “Global Fusion Biopsy Market Size“
202 – Pages
126 – Tables
37 – Figures
Report Scope
REPORT ATTRIBUTES
DETAILS
STUDY PERIOD
2021-2032
BASE YEAR
2024
FORECAST PERIOD
2025-2032
HISTORICAL PERIOD
2021-2023
UNIT
Value (USD Million)
KEY COMPANIES PROFILED
Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.
SEGMENTS COVERED
Biopsy Route, Product, End User, And Geography.
CUSTOMIZATION SCOPE
Free report customization (equivalent to up to 4 analyst working days) with purchase. Addition or alteration to country, regional & segment scope
Global Fusion Biopsy Market Overview
Key Market Drivers
Rising Prevalence of Prostate Cancer and Need for Early Diagnosis: The rising global prevalence of prostate cancer significantly propels the Fusion Biopsy Market. Conventional biopsy techniques frequently result in false negatives, postponing essential therapies. Fusion biopsy, integrating MRI and ultrasound, improves precision and early diagnosis, establishing it as the preferred method for urologists and oncologists. As healthcare providers emphasize precision diagnostics, the need for fusion biopsy systems is anticipated to increase, propelling market expansion.
Technological Advancements in Imaging and AI Integration: The advancement of MRI-ultrasound fusion biopsy technology, enhanced by artificial intelligence and real-time imaging, is revolutionizing cancer diagnoses. AI-driven automation enhances lesion diagnosis and biopsy targeting, minimizing mistakes and increasing productivity. The Fusion Biopsy Market is experiencing swift adoption in hospitals and diagnostic centers as manufacturers invest in advanced imaging systems. Organizations utilizing AI-driven biopsy advancements will acquire a significant competitive advantage.
Increasing Investments and Favorable Regulatory Approvals: Government entities and private investors are significantly financing precision diagnostic solutions, hence generating development prospects in the Fusion Biopsy Market. Beneficial FDA approvals and efficient regulatory frameworks are accelerating product introductions and promoting innovation. Increasing healthcare expenditures and reimbursement policies favoring sophisticated biopsy treatments are enhancing market penetration. Enterprises that use regulatory changes will experience substantial revenue growth.
To Purchase a Comprehensive Report Analysis: https://www.verifiedmarketresearch.com/select-licence?rid=480739
Market Restraints Hindering the Market Growth
High Cost of Fusion Biopsy Systems and Procedures: Notwithstanding its clinical benefits, the Fusion Biopsy Market encounters obstacles owing to the substantial expense of MRI-ultrasound fusion biopsy devices. Advanced imaging technology and AI-driven biopsy instruments necessitate significant investment, constraining adoption by small and medium-sized healthcare institutions. Cost-sensitive markets, especially in emerging areas, face challenges with affordability, hindering widespread implementation and impeding market growth.
Limited Access to Skilled Radiologists and Urologists: The efficacy of fusion biopsy is contingent upon the proficiency of radiologists and urologists skilled in MRI-ultrasound-guided techniques. A deficiency of trained professionals, particularly in emerging regions, is constraining market expansion. Healthcare facilities encounter difficulties in adopting and optimizing fusion biopsy technologies without enough training. Mitigating this deficiency through educational and certification initiatives is essential for fostering enduring adoption and maintaining growth in the Fusion Biopsy Market.
Stringent Regulatory Requirements and Approval Delays: Despite the rise in regulatory approvals, rigorous compliance mandates and protracted approval procedures present obstacles for new market entrants. The Fusion Biopsy Market has intricate clinical validation procedures, hindering product commercialization. Companies must manage changing rules, which can impede innovation and delay market entry. Organizations that strategically adhere to compliance requirements will be more equipped to navigate these challenges and foster continuous growth.
Geographical Dominance:
North America Leads the Fusion Biopsy Market with Advanced Healthcare Infrastructure
North America leads the Fusion Biopsy Market, propelled by advanced healthcare infrastructure, widespread acceptance of precision diagnostics, and increasing incidences of prostate cancer. The United States excels in robust research and development spending and advantageous reimbursement policies, facilitating industry growth. This supremacy draws international entities, promoting innovation and technical progress. As demand escalates, enterprises focusing on North America have a competitive advantage in revenue expansion.
Key Players
The “Global Fusion Biopsy Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Eigen, Koninklijke Philips N.V., Hitachi Ltd., Focal Healthcare, MedCom, ESAOTE SPA, KOELIS, BK Medical Holding Company Inc., Biobot Surgical Pte Ltd, Exact Imaging, and UC-Care Medical Systems Ltd.
Fusion Biopsy Market Segment Analysis
Based on the research, Verified Market Research has segmented the market into Biopsy Route, Product, End User, and Geography.
Fusion Biopsy Market, by Biopsy RouteTransrectalTransperinealFusion Biopsy Market, by ProductEquipmentConsumablesFusion Biopsy Market, by End-UserHospitalsDiagnostic CentersAmbulatory Care CentersAcademic & Research LaboratoriesFusion Biopsy Market, by GeographyNorth AmericaU.SCanadaMexicoEuropeGermanyFranceU.KRest of EuropeAsia PacificChinaJapanIndiaRest of Asia PacificROWMiddle East & AfricaLatin America
Browse Related Reports:
Global Liquid Biopsy Market Size By Biomarker (Circulating Tumor Cells, Circulating Nucleic Acids), By Technology (NGS, PCR Microarrays), By Application (Cancer, Reproductive Health), End-User (Hospitals, Specialty Clinics), By Geography, And Forecast
Global Biopsy Devices Market Size By Product (Instruments For Needle-Based Biopsy, Biopsy Guidance Systems, Biopsy Needles (Disposable, Reusable), Biopsy Forceps), By End User (Hospitals & Clinics, Diagnostic Imaging Centres, Research Labs & Pharmaceutical Companies), By Application (Breast Biopsy, Bone Marrow Biopsy, Colorectal Biopsy, Lung Biopsies, Prostate Biopsies), By Geography, And Forecast
Global Plastic Surgery And Integumentary System Procedures Market Size By Procedure (Prefilled Syringe Biopsy, Excisional Biopsy), By Operating Area (Eyelids, Subcutaneous Tissue), By Application (Skin Grafts, Allograft), By End User (Hospitals And Clinics, Research Laboratories), By Geography, And Forecast
Global Biopsy Needles Market Size By Product Type (Biopsy Needles, Aspiration Needles), By Application (Tumor/Cancer Applications, Wound Applications), By Procedure (Image-guided Procedures, Non-image-guided Procedures), By End-User (Hospitals & Surgical Centers, Diagnostic Clinics & Pathology Laboratories, Ambulatory Care Centers, Research & Academic Institutes), By Geography, And Forecast
Top 7 Implantable Medical Device Companies advancing patient care
Visualize Fusion Biopsy Market using Verified Market Intelligence -:
Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.
VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.
About Us
Verified Market Research® stands at the forefront as a global leader in Research and Consulting, offering unparalleled analytical research solutions that empower organizations with the insights needed for critical business decisions. Celebrating 10+ years of service, VMR has been instrumental in providing founders and companies with precise, up-to-date research data.
With a team of 500+ Analysts and subject matter experts, VMR leverages internationally recognized research methodologies for data collection and analyses, covering over 15,000 high impact and niche markets. This robust team ensures data integrity and offers insights that are both informative and actionable, tailored to the strategic needs of businesses across various industries.
VMR’s domain expertise is recognized across 14 key industries, including Semiconductor & Electronics, Healthcare & Pharmaceuticals, Energy, Technology, Automobiles, Defense, Mining, Manufacturing, Retail, and Agriculture & Food. In-depth market analysis cover over 52 countries, with advanced data collection methods and sophisticated research techniques being utilized. This approach allows for actionable insights to be furnished by seasoned analysts, equipping clients with the essential knowledge necessary for critical revenue decisions across these varied and vital industries.
Verified Market Research® is also a member of ESOMAR, an organization renowned for setting the benchmark in ethical and professional standards in market research. This affiliation highlights VMR’s dedication to conducting research with integrity and reliability, ensuring that the insights offered are not only valuable but also ethically sourced and respected worldwide.
Contact Us
Mr. Edwyne Fernandes
Verified Market Research®
US: +1 (650)-781-4080
US Toll Free: +1 (800)-782-1768
Email: sales@verifiedmarketresearch.com
Web: https://www.verifiedmarketresearch.com/
Follow Us: LinkedIn | Twitter | Threads | Instagram | Facebook
Logo: https://mma.prnewswire.com/media/2015407/VMR_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fusion-biopsy-market-is-expected-to-generate-a-revenue-of-usd-1448-15-million-by-2032–globally-at-8-9-cagr-verified-market-research-302393044.html
You may like
Technology
Volvo Cars Q3 2026: taking decisive action to navigate a very tough environment
Published
48 minutes agoon
October 23, 2026By
GOTHENBURG, Sweden, Oct. 23, 2026 /PRNewswire/ — Volvo Cars today reports an operating income, excluding joint ventures & associates and items affecting comparability, of SEK -3.7 billion and a corresponding EBIT margin of -5.6 per cent for the third quarter of 2026. The result reflects a further deteriorating external environment, led by market developments in China and the US.
Q3 revenue was SEK 66.9 bn (SEK 86.4 bn in Q3 2025)Q3 operating income was SEK -5.6 bn (SEK 6.4 bn in Q3 2025)Q3 EBIT (excl. share of income in JVs & associates and IAC) was SEK -3.7 bn (SEK 5.8 bn in Q3 2025)Q3 EBIT margin was -8.4 per cent (7.4 per cent in Q3 2025)Q3 EBIT margin (excl. share of income in JVs & associates and IAC) of -5.6 per cent (6.7 per cent in Q3 2025)Q3 basic earnings per share were SEK -1.63 (SEK 1.75 in Q3 2025)Q3 fully electric car sales share at 32 per cent (22 per cent in Q3 2025)Q3 electrified car sales share at 53 per cent (46 per cent in Q3 2025)Q3 free cash flow of SEK -8.9 billion (SEK -4.3 billion in Q3 2025)
Volvo Cars today reports an operating income, excluding joint ventures & associates and items affecting comparability, of SEK -3.7 billion and a corresponding EBIT margin of -5.6 per cent for the third quarter of 2026. The result reflects a further deteriorating external environment, led by market developments in China and the US.
Volvo Cars remains a leader in the premium fully electric (BEV) segment, underpinned by a resilient performance in Europe where it had a BEV sales share of 45 per cent in Q3. But the situation in China and the US was considerably tougher, which also negatively affected free cash flow.
In China, Volvo Cars and other legacy premium brands faced hypercompetition from new Chinese alternatives, as well as severe pricing pressure. As a result, Volvo Cars’ revenues in China fell by almost 50 per cent year-on-year. In the US, Volvo Cars saw continued negative effects from tariffs and the removal of consumer incentives for electrified cars, which pressured margins.
The company’s Q3 result was also affected by other external developments: a negative revaluation of SEK 1.1 billion in CAFE credits due to legislation changes in the US, negative raw material developments, and SEK -0.9 billion due to the recognition of Polestar’s losses in Q2 2026.
In response to the result, Volvo Cars aims to reduce an additional SEK 5 billion in indirect spend and variable costs, on top of earlier cost programmes it successfully completed. These actions will lead to a structural reduction of approximately 2,500 jobs globally, of which 2,000 are based in Sweden, by ending consultant contracts, through natural attrition and by targeted exit packages to employees.
Full financial effects of these measures will be realised by the end of 2027, by which time the company’s overall indirect spend will be almost 25 per cent lower versus FY 2024.
The company is also working at speed on its recently announced, largest-ever product push. This consists of 13 new cars between now and the end of 2030, with a tailored portfolio of new cars for Europe, the US and China and more localised production. Already in 2027, Volvo Cars will reveal three of these new cars: one new car for Europe and two China-specific models.
More details about Volvo Cars’ performance can be found in the Q3 2026 financial report.
“We continue to operate in a very tough environment with strong external challenges: de-globalisation, hypercompetition and climate change. We are convinced that we have the right long-term strategy addressing these challenges,” says Håkan Samuelsson, president and CEO. “However, in the short term, with severely challenged volumes, we need to reinforce our turnaround plan with additional decisive actions, lowering our break-even point and improving cash flows to make us more resilient.”
A reinforced turnaround plan with the right regional products
Reflecting its strong BEV position in Europe, the EX60 has been a big success with over 50,000 European orders and it will be one of Volvo Cars’ most profitable models. Due to new industrial technology such as cell-to-body it is taking longer than planned to ramp up production, but Volvo Cars is steadily improving built volumes.
In 2027 Volvo Cars will introduce its next global BEV car, which targets a large, lower priced market segment in Europe, with the first customer deliveries starting after summer. This will further strengthen its BEV leadership and improve margins.
In the US, Volvo Cars has divided the market in four regions to enable faster decision-making and improve sales. It is fast-tracking the production start of the long-range plug-in hybrid versions of the XC90 and XC60, with European deliveries starting this year and the US shortly after. In Q1 2027, it will localise XC60 production in Charleston. By the end of the decade, it will localise a second, all-new car with multiple powertrain options.
In China, the next two years will remain tough, so Volvo Cars is taking further cost-efficiency actions to weather the storm. For example, it will combine its two offices in Shanghai by moving the sales office to the local HQ in Jiading.
Mid-next year Volvo Cars will reveal and start production of the first two of six new China-tailored cars, through closer cooperation with Geely. These cars will be developed with a Chinese tech stack and the latest ADAS technologies to make them fully competitive in China.
Additional cost and cash actions
Volvo Cars will achieve the additional savings of SEK 5 billion by driving structural change, lowering corporate overheads and empowering its regions. It is adapting its blue-collar workforce to current volumes by leveraging existing flexibility and will continue to reduce R&D costs, as it has already established its tech foundation with SPA3 and HuginCore.
Volvo Cars will also develop a more efficient production structure by concentrating on five dedicated Volvo plants globally. For its Chengdu and Ghent plants the company is exploring the option of multi-brand assembly together with Geely.
In addition, the company will further lower its variable costs, for example by increasing its common supplier base with Geely Group and adopting more common hardware parts in its cars.
Finally, Volvo Cars will continue to prioritise cash. The company has passed its investment peak and has now returned to normal and affordable investment levels, corresponding to an approximately 30 per cent reduction compared to 2024.
Note to editors
Volvo Cars will host a livestream on its Q3 2026 results for media, investors and analysts at 08:00 CET today. The presentation will be held in English and followed by a Q&A session.
It will be possible to ask questions during the Q&A session following the main presentation. To participate, you can either use the chat function online to type your question, or you can call in. To call in, participants need to register via the link below and will then receive the dial-in details and individual PIN.
This disclosure contains information that Volvo Car AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-10-2026 07:00 CET.
For further information please contact:
Volvo Cars Media Relations
+46 31-59 65 25
media@volvocars.com
Volvo Cars Investor Relations
+46 31-793 94 00
investors@volvocars.com
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/20685/4414242/4335538.pdf
VCG_ENG_Q3 2026-10-23
https://news.cision.com/volvo-car-ab–publ-/i/jpg-medium-ste-1901-xc90-lr,c3575569
JPG Medium-STE 1901 XC90 LR
View original content:https://www.prnewswire.com/news-releases/volvo-cars-q3-2026-taking-decisive-action-to-navigate-a-very-tough-environment-302917802.html
SOURCE Volvo Car AB (publ)
Technology
Artery AT32 AI Studio Empowers Edge Intelligence, Accelerating AI Application Deployment
Published
48 minutes agoon
October 23, 2026By
TAIPEI, Oct. 23, 2026 /PRNewswire/ — As artificial intelligence (AI) technology continues to advance rapidly, AI is expanding from cloud computing to edge devices, with applications such as intelligent sensing, voice interaction, and visual recognition increasingly being integrated into a wide range of end devices.
Focusing on the development of edge intelligence, Artery continues to strengthen its AT32 ecosystem with AT32 AI Studio, a one-stop edge AI development platform designed to help developers efficiently build and deploy edge AI applications on AT32 MCUs, lower the barriers to AI development, and accelerate the transition from AI models to real-world products.
An Integrated Toolchain Streamlining the Entire Edge AI Development Process
AT32 AI Studio integrates key capabilities throughout the edge AI development process, including data processing, model training and optimization, simulation and validation, and code generation, into a unified development environment. This integration helps developers reduce tool switching and repetitive configuration, enabling more efficient integration of AI models into AT32 MCU applications.
With its graphical development workflow and automated code generation capabilities, developers can build AI applications more intuitively and quickly convert optimized models into embedded code compatible with the AT32 platform, further shortening the development cycle from algorithm validation to product implementation.
Optimized for Edge Computing, Enabling Lightweight AI Model Deployment
For resource-constrained embedded devices, model size, memory usage, computational requirements, and power consumption often directly determine whether AI applications can be successfully deployed.
AT32 AI Studio provides model optimization capabilities tailored to edge deployment requirements. Through techniques such as quantization and compression, the platform reduces model storage and computational resource requirements while maintaining accuracy and improving execution efficiency on AT32 MCUs. In addition, the platform includes lightweight neural network models designed for embedded applications, providing developers with an AI development foundation better suited to the resource constraints of MCUs. These capabilities enable AI algorithms to move beyond basic execution toward practical deployment and real-world applications.
Unlocking the Potential of AT32 Edge AI Across Diverse Applications
AT32 AI Studio has been successfully applied to various scenarios, including voice keyword recognition, Time-of-Flight (ToF)-based gesture recognition, and industrial anomaly detection, demonstrating its versatility. By leveraging AT32 AI Studio, developers can combine AI algorithms with the hardware capabilities of AT32 MCUs to enhance sensing and decision-making capabilities in end devices, expanding the potential of MCU-based applications in smart homes, industrial control, smart wearables, and human-machine interaction.
Focused on Practical Deployment, Bringing AI Development Closer to Real-World Products
For embedded AI applications, successful execution of a model on a PC does not necessarily guarantee stable operation on actual hardware. Model accuracy, resource utilization, and real-world performance must still be validated in the target hardware environment.
AT32 AI Studio incorporates simulation, evaluation, and practical deployment as essential stages of the development process, establishing a complete development–validation–deployment workflow. This approach helps developers thoroughly evaluate model performance on the AT32 platform during development, while automated code generation further facilitates integration with embedded software development.
Empowering the Ecosystem with Development Tools and Accelerating the Transition to Edge Intelligence
As applications evolve from traditional control to intelligent sensing, MCUs are becoming an important platform for extending AI capabilities to end devices. Artery Technology continues to enhance its software ecosystem and development toolchain centered on AT32 MCUs, reducing development complexity, improving model deployment efficiency, and providing developers with more comprehensive and efficient AI development support.
AT32 AI Studio represents an important part of Artery’s AI ecosystem development, bridging Physical AI and edge computing. Through an end-to-end development workflow, MCU-oriented model optimization, and automated deployment capabilities, Artery Technology will further unlock the potential of edge AI applications on the AT32 platform, helping developers integrate AI capabilities into end products more efficiently and bringing more intelligent applications from algorithms to reality.
Artery Technology specializes in the research, development, and innovation of 32-bit microcontrollers, providing high-performance, highly reliable products and solutions for a wide range of applications, including industrial control, consumer electronics, IoT, and smart applications. The company is committed to advancing intelligent technologies through continuous innovation.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/artery-at32-ai-studio-empowers-edge-intelligence-accelerating-ai-application-deployment-302917813.html
SOURCE Artery Technology
STOCKHOLM, Oct. 23, 2026 /PRNewswire/ —
Highlights of the third quarter of 2026
Net sales increased to SEK 33,919m (32,318) with organic sales growth of 3.5% (4.6). All regions contributed to the growth, driven mainly by increased sales volumes in Europe, Middle East & Africa, Asia Pacific (EMEA APAC), and Latin America, as well as positive price development in North America.Operating income excluding non-recurring items (NRIs) was SEK 912m (890), corresponding to a margin of 2.7% (2.8). Cost efficiency contributed SEK 1.4bn to operating income, offsetting the significant negative impact from external factors, primarily from increased raw material and logistics cost as a consequence of the Middle East conflict, and U.S. tariff costs.Operating income of SEK 607m (890), corresponding to an operating margin of 1.8% (2.8), included negative NRIs of SEK -305m referring to previously announced restructuring costs related to the strategic partnership with Midea Group in North America, and global organization and footprint optimization costs. In the quarter, the factory in Rosario, Argentina, was closed.Income for the period was SEK -340m (192) and earnings per share were SEK -0.46 (0.39).Operating cash flow after investments was SEK 3,608m (624), mainly driven by improved working capital, and U.S. tariff refunds. Investments continued to be at a low level.Net debt/EBITDA improved to 2.2x (3.5).Manufacturing joint venture in Anderson, U.S., for Fabric Care, with Midea Group in North America, became operational on September 1.
Events after the close of the period:
Sales joint venture, U.S., and manufacturing joint venture in Juarez, Mexico, with Midea Group in North America related to Food Preservation products became operational on October 1.
President and CEO Yannick Fierling’s comment
Strong strategic execution and resilient performance
The third quarter marked strong progress in the transformation of Electrolux Group. We continued to execute the strategic priorities and delivered resilient performance in a challenging market environment. Competitive pressure remained high, alongside significant cost headwinds from external factors, including raw material, logistic costs and U.S. tariffs.
In North America, we reached an important milestone as our strategic partnership with Midea Group became operational. All three joint ventures have been established, including the sales joint venture for Food Preservation and the manufacturing joint ventures in Juarez, Mexico, and Anderson, U.S. The closure of the Anderson factory contributed positively to earnings in the quarter. The repurposing of the site for laundry production is progressing according to plan. The sale of the Juarez assets to Midea Group was completed on October 1.
Across the Group, we continued to progress on the global organization and manufacturing footprint optimization. We are creating a leaner organization, with fewer employees and a greater share of resources closer to consumers and markets. In the third quarter, we closed the factory in Rosario, Argentina. In Italy, discussions with trade unions and institutions regarding the optimization plan are progressing according to plan.
Navigating diverse regional challenges
In North America, inflation concerns continued to weigh on consumer confidence. Demand shifted towards lower price points as consumers are impacted by inflation and prioritize affordability. Higher tariffs added significant cost pressure, forcing the industry to further increase prices in the quarter. In Europe, consumer confidence deteriorated as geopolitical uncertainty increased and inflation weighed on purchasing power and demand. In Brazil, market demand remained positive, although growth slowed significantly as elevated interest rates continued to affect consumers’ financing and household spending.
Organic sales growth and strong cash generation
Organic sales grew in the quarter, with resilient performance across all regions. Strong commercial execution enabled us to increase our value market share for both the Electrolux and the AEG brands in Europe. In Latin America, growth was driven by higher volumes. In North America, organic sales growth mainly reflected the price increases implemented to mitigate higher tariff costs.
Operating income excluding non-recurring items was positively impacted by cost efficiency. This was offset by significant external headwinds, with the Middle East conflict impacting with full effect, leading to substantially higher raw material and logistics costs. U.S. tariff costs also had a negative impact in the quarter. We expect the pressure from external factors to remain in the coming quarters. Operating income benefited from a positive effect related to a recovery claim for overpaid tax, included in cost efficiency. This more than offset the negative effect from a customer-related provision in Brazil.
Operating cash flow after investment improved to SEK 3.6bn, supported by improved operating working capital and U.S. tariff refunds. The leverage ratio improved to 2.2x.
Full-year 2026 business and market outlook
We now expect volume, price and mix combined to have a neutral operating income contribution, compared with previously positive, reflecting the challenging market environment across regions. The expected contribution from cost efficiency is changed to about SEK 4.0bn, reflecting the strong traction in our cost efficiency initiatives. The business outlook for investments in consumer experience innovation and marketing, external factors and capital expenditure remains unchanged, as does our regional market outlook.
Building long-term competitiveness
We remain focused on what we can control to win in the marketplace: resetting North America operations, optimizing our organization and manufacturing footprint, and capturing growth opportunities.
We are reshaping Electrolux Group into a more agile, competitive and consumer-centric company. I am proud of the performance in the third quarter and the commitment and drive across Electrolux Group as we continue our transformation.
Webcast and telephone conference 09.00 CEST
A video webcast and simultaneous telephone conference is held at 09.00 CEST today, October 23. Yannick Fierling, President and CEO, and Therese Friberg, CFO, will comment on the report.
If you wish to participate via webcast, please use the link below. Via the webcast you are able to ask written questions.
https://edge.media-server.com/mmc/p/pb2vmwpk/
If you wish to participate via telephone conference, please register on the link below. After registration, you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://register-conf.media-server.com/register/BI00fde9a3778945cbb8a8c2c1c778f2cb
The press release and presentation material is available for download on the Investor Relations section on electroluxgroup.com.
This is information that AB Electrolux is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 23-10-2026 07:00 CET.
For more information:
Ann-Sofi Jönsson, Head of Investor Relations & Sustainability Reporting, ann-sofi.jonsson@electrolux.com, +46 73 025 1005
Maria Åkerhielm, Investor Relations Manager, maria.akerhielm@electrolux.com, +46 70 796 3856
Henry Sjölin, Investor Relations Manager, henry.sjolin@electrolux.com, +46 76 863 51 85
Electrolux Press Hotline, +46 8 657 65 07.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/electrolux-group/r/electrolux-group-interim-report-q3-2026,c4414138
The following files are available for download:
https://mb.cision.com/Main/1853/4414138/4335007.pdf
Interim report – ENG – Q3 2026
View original content:https://www.prnewswire.com/news-releases/electrolux-group-interim-report-q3-2026-302917815.html
SOURCE Electrolux Group
Volvo Cars Q3 2026: taking decisive action to navigate a very tough environment
Artery AT32 AI Studio Empowers Edge Intelligence, Accelerating AI Application Deployment
Electrolux Group Interim report Q3 2026
Send Rakhi to UK swiftly with UK Gifts Portal
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
Nullmax and Renesas Forge Strategic Partnership to Deliver Competitive ADAS Solutions for the Global Market
Why You Should Build on #NEAR – Co-founder Illia Polosukhin at CV Labs
Whiteboard Series with NEAR | Ep: 45 Joel Thorstensson from ceramic.network
NEAR End of Year Town Hall 2021: The Open Web World, MetaBUILD 2 Hackathon and 2021 recap
Trending
-
Technology4 days agoGMIF2026: AI Inference Powers the “Token Factory” and Drives System-Level Rethinking of Memory & Storage
-
Technology4 days agoInstaMall Launches Same-Day Fashion Delivery Experience, Bringing 80+ Brands to Shoppers’ Doors in Miami
-
Coin Market4 days agoWorld Liberty’s USD1 stablecoin sheds $400M in market cap in two weeks
-
Technology4 days agoTruecaller announces preliminary numbers for the third quarter 2026
-
Technology4 days agoHISTOINDEX AND A*STAR PARTNER TO ADVANCE EARLY-STAGE DEVELOPMENT OF PIPELINE THERAPIES FOR FIBROTIC DISEASES
-
Technology4 days agoSALMON SECURES $140 MILLION (PHP 8.8 BILLION) TO DOUBLE DOWN ON THE GROWTH OPPORTUNITY IN THE PHILIPPINES
-
Technology4 days agoTrend Micro Announces Up to ¥10 Billion toward Cyber Resilience Initiative to Strengthen Security for Japanese Organizations in the AI Era
-
Technology5 days agoLinktel Technologies Highlights Breakthrough 1.6T LPO Performance & Strong Market Pull at OCP 2026
